Bioprocess optimisation for liver organoid biomanufacturing

Liver transplants can be a lifesaving treatment for people living with liver disease. However, many patients die on the waiting list every year. This major concern has raised the need to find alternatives to organ replacement therapy. Morphocell Technologies’ product, ReLiver™, uses stem cells to treat liver disease. Stem cells have the ability to self-renew and develop into different tissue types. In this case, the stem cells are developed into liver cells by following a multistage protocol. The 3D structures formed as a result of this protocol are called organoids. These organoids are then enveloped in a hydrogel to create the drug product. However, organoids composed of multiple cell types, complicate manufacturing, quality control, and quality assurance. Removing one or more cell types from the process would streamline production from a cost and manufacturability perspective.
Improving the ReLiver™ manufacturing process could significantly impact the lives of Canadians living with hepatic disease. This project aims to simplify the manufacturing process. This could reduce cost and accelerate access to the therapy.

Faculty Supervisor:

Corinne A Hoesli

Student:

Partner:

Morphocell Technologies

Discipline:

Engineering

Sector:

Professional, scientific and technical services

University:

McGill University

Program: